Exploring MicroRNA and Exosome Involvement in Malignant Pleural Mesothelioma Drug Response.

Abstract

Simple SummaryMalignant pleural mesothelioma (MPM) is a deadly thoracic malignancy with limited treatment options. Chemotherapy remains the most widely used first-line treatment for unresectable MPM but is hampered by drug resistance issues. Small molecule inhibitors and microRNA mimics have shown promising potential for the treatment of MPM in preclinical studies, but are yet to be successfully implemented in the clinical setting. Our study aims to provide an understanding of the molecular mechanism(s) that mediate drug response in MPM. The inhibitor of apoptosis family member, survivin, has been reported to be over-expressed in MPM and is associated with drug resistance. Therefore, we particularly focused on determining the cellular mechanism(s) that contribute to MPM cell response to a survivin small molecule inhibitor, YM155. Our study provides key information to facilitate a prediction of the potential utility of small molecule inhibitors and microRNA mimics as treatment options for MPM.Malignant pleural mesothelioma (MPM) is a deadly thoracic malignancy and existing treatment options are limited. Chemotherapy remains the most widely used first-line treatment regimen for patients with unresectable MPM, but is hampered by drug resistance issues. The current study demonstrated a modest enhancement of MPM cell sensitivity to chemotherapy drug treatment following microRNA (miRNA) transfection in MPM cell lines, albeit not for all tested miRNAs. This effect was more pronounced for FAK (PND-1186) small molecule inhibitor treatment; consistent with previously published data. We previously established that MPM response to survivin (YM155) small molecule inhibitor treatment is unrelated to basal survivin expression. Here, we showed that MPM response to YM155 treatment is enhanced following miRNA transfection of YM155-resistant MPM cells. We determined that YM155-resistant MPM cells secrete a higher level of exosomes in comparison to YM155-sensitive MPM cells. Despite this, an exosome inhibitor (GW4896) did not enhance MPM cell sensitivity to YM155. Additionally, our study showed no evidence of a correlation between the mRNA expression of inhibitor of apoptosis (IAP) gene family members and MPM cell sensitivity to YM155. However, two drug transporter genes, ABCA6 and ABCA10, were upregulated in the MPM cell lines and correlated with poor sensitivity to YM155.